Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in healthy Adults participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ABBV-932 with Itraconazole | Experimental | Participants will receive ABBV-932 in Period 1 followed by Itraconalzole in combination with ABBV-932 in Period 2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABBV-932 | Drug | Oral Capsule |
| |
| Itraconazole |
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAR | Cmax of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Time to Cmax (Tmax) of ABBV-932 and active metabolites DCAR and DDCAR | Tmax of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932 and active metabolites DCAR and DDCAR | Ctrough of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Apparent terminal phase elimination rate constant (β) of ABBV-932 and active metabolites DCAR and DDCAR | (β) of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Terminal Phase Elimination Half-Life (t1/2) of ABBV-932 and active metabolites DCAR and DDCAR | Terminal phase elimination half-life of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932 and active metabolites DCAR and DDCAR | AUCt of ABBV-932 and active metabolites DCAR and DDCAR | Up to approximately 29 days |
| Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932 and active metabolites DCAR and DDCAR |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Acpru /Id# 276951 | Grayslake | Illinois | 60030 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017964 | Itraconazole |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Oral Capsule |
|
|
AUCinf of ABBV-932 and active metabolites DCAR and DDCAR |
| Up to approximately 29 days |
| Number of Participants Experiencing Adverse Events | An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. | Up to approximately 61 days |
| D010879 |
| Piperazines |